<Just discovered your thread and find it really great. Where have you guys been hiding?>
We haven't been hiding Mightycujo. Just that we're low key. So, it's
PGEN that you're interested in. Amigo Mike has a better grasp of the medical stocks, but I'll throw my two cents in. PGEN activity seems to have picked up resulting from the annual meeting last week. Interesting company on first glance and maybe worth looking at a little deeper. What do you think Mike?
I'm sure that you've probably seen this release, but for those not familiar with PGEN:
Researching genes to identify targets for the development of new pharmaceuticals. IPO at $7 August 06, 1997.
Published Date: Feb. 27, 1998
Company Name: Progenitor, Inc.
Address: 4040 Campbell Ave.
Menlo Park, CA 94025
Main Telephone
Number: 650/617-0880
Internet Home
Page Address
(URL): www.progenitor.com
Chief Executive
Officer: Douglass B. Given, M.D., Ph.D.
Chief Financial
Officer: Mark N.K. Bagnall
Investor Relations
Contact: Andrea Yamartino
Business number: 650/614-7099
Home number: 650/328-5240
Public Relations
Contact: Carrie B. Wick
Business number: 650/614-7060
Home number: 614/436-3075 (based in Ohio currently)
Trading Symbol/
Exchange: PGEN, PGENW
Industry: Genomics/Biotech
Market Makers: Lehman Brothers, Genesis Merchant Group, Herzog,
Nash Weiss, Knight, Meyerson, Josephthal, Troster
Singer, Neidiger
Company description: Progenitor is engaged in the discovery and
functional characterization of genes to identify targets for the
development of new pharmaceuticals. The company's focus is on the
identification of genes important in cancer, blood and immune system
disorders and inherited diseases. Progenitor's genomics system focuses
on understanding gene function in order to accelerate discovery of
genes with medical relevance. The system combines core expertise in the
fields of developmental biology, human disease genetics and
bioinformatics, using developing cells and rigorously screened patient
populations as unique discovery resources.
The company's gene discoveries include B219, which encodes the leptin
receptor; de/-1, involved in blood vessel and bone formation; and HFE,
responsible for hereditary hemochromatosis, an iron overload disease.
Progenitor develops and commercializes its discoveries through
partnerships with biopharmaceutical firms. The company has ongoing
agreements with Amgen, SmithKline Beecham Clinical Laboratories, Novo
Nordisk, Chiron, Pangea Systems, and Affymetrix. |
